Greenwich LifeSciences (NASDAQ:GLSI) Issues Quarterly Earnings Results, Misses Estimates By $0.34 EPS

Greenwich LifeSciences (NASDAQ:GLSI) released its quarterly earnings data on Monday. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.34), FiscalAI reports.

Greenwich LifeSciences Stock Performance

GLSI stock traded up $2.34 during trading on Monday, hitting $28.51. 217,974 shares of the company’s stock traded hands, compared to its average volume of 273,670. Greenwich LifeSciences has a 52 week low of $7.78 and a 52 week high of $34.10. The business has a fifty day simple moving average of $24.98 and a 200 day simple moving average of $21.90. The stock has a market capitalization of $394.86 million, a price-to-earnings ratio of -19.53 and a beta of 1.40.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Man Group plc bought a new position in Greenwich LifeSciences in the 4th quarter worth about $590,000. State Street Corp increased its position in Greenwich LifeSciences by 19.3% during the 4th quarter. State Street Corp now owns 97,777 shares of the company’s stock valued at $2,054,000 after purchasing an additional 15,831 shares during the period. Goldman Sachs Group Inc. increased its position in Greenwich LifeSciences by 8.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 21,545 shares of the company’s stock valued at $453,000 after purchasing an additional 1,700 shares during the period. Citadel Advisors LLC boosted its holdings in shares of Greenwich LifeSciences by 52.1% in the 3rd quarter. Citadel Advisors LLC now owns 20,942 shares of the company’s stock valued at $208,000 after buying an additional 7,174 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Greenwich LifeSciences by 4.9% in the 3rd quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock valued at $2,808,000 after buying an additional 13,179 shares in the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GLSI. Weiss Ratings reissued a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Friday, May 15th. Wall Street Zen raised shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $47.50.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.